Read by QxMD icon Read


shared collection
3 papers 100 to 500 followers
By Brooke Manor Endocrinology
Pamela M Rist, Benjamin D Capistrant, Qiong Wu, Jessica R Marden, M Maria Glymour
OBJECTIVE: To identify modifying factors that preserve functional independence among individuals at high dementia risk. METHODS: Health and Retirement Study participants aged 65 years or older without baseline activities of daily living (ADL) limitations (n = 4,922) were interviewed biennially for up to 12 years. Dementia probability, estimated from direct and proxy cognitive assessments, was categorized as low (i.e., normal cognitive function), mild, moderate, or high risk (i...
April 29, 2014: Neurology
Kit Yee Chan, Wei Wang, Jing Jing Wu, Li Liu, Evropi Theodoratou, Josip Car, Lefkos Middleton, Tom C Russ, Ian J Deary, Harry Campbell, Wei Wang, Igor Rudan
BACKGROUND: China is increasingly facing the challenge of control of the growing burden of non-communicable diseases. We assessed the epidemiology of Alzheimer's disease and other forms of dementia in China between 1990, and 2010, to improve estimates of the burden of disease, analyse time trends, and inform health policy decisions relevant to China's rapidly ageing population. METHODS: In our systematic review we searched for reports of Alzheimer's disease or dementia in China, published in Chinese and English between 1990 and 2010...
June 8, 2013: Lancet
Anton P Porsteinsson, Lea T Drye, Bruce G Pollock, D P Devanand, Constantine Frangakis, Zahinoor Ismail, Christopher Marano, Curtis L Meinert, Jacobo E Mintzer, Cynthia A Munro, Gregory Pelton, Peter V Rabins, Paul B Rosenberg, Lon S Schneider, David M Shade, Daniel Weintraub, Jerome Yesavage, Constantine G Lyketsos
IMPORTANCE: Agitation is common, persistent, and associated with adverse consequences for patients with Alzheimer disease. Pharmacological treatment options, including antipsychotics are not satisfactory. OBJECTIVE: The primary objective was to evaluate the efficacy of citalopram for agitation in patients with Alzheimer disease. Key secondary objectives examined effects of citalopram on function, caregiver distress, safety, cognitive safety, and tolerability. DESIGN, SETTING, AND PARTICIPANTS: The Citalopram for Agitation in Alzheimer Disease Study (CitAD) was a randomized, placebo-controlled, double-blind, parallel group trial that enrolled 186 patients with probable Alzheimer disease and clinically significant agitation from 8 academic centers in the United States and Canada from August 2009 to January 2013...
February 19, 2014: JAMA: the Journal of the American Medical Association
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"